Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Study Information
Alliance Study ID: A021901
NCT Study ID (ClinicalTrials.gov): NCT04665739
Alliance Committee: Gastrointestinal Cancer
Disease or Cancer Type: Lung Cancer & Mesothelioma
Alliance Study Chair: Thomas A Hope
Status: RECRUITING
Study Description
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Locations (29)
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama 35233
United States
Tower Cancer Research Foundation
Beverly Hills, California 90211
United States
Loma Linda University Medical Center
Loma Linda, California 92354
United States
Cedars-Sinai Medical Center
Los Angeles, California 90048
United States
UCSF Medical Center-Mission Bay
San Francisco, California 94158
United States
Torrance Memorial Physician Network – Cancer Care
Torrance, California 90505
United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia 20007
United States
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida 33180
United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida 33146
United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida 33442
United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida 33136
United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida 33324
United States
University of Chicago Comprehensive Cancer Center
Chicago, Illinois 60637
United States
UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois 60451
United States
University of Chicago Medicine-Orland Park
Orland Park, Illinois 60462
United States
UI Health Care Mission Cancer and Blood – Ankeny Clinic
Ankeny, Iowa 50023
United States
Iowa Methodist Medical Center
Des Moines, Iowa 50309
United States
UI Health Care Mission Cancer and Blood – Des Moines Clinic
Des Moines, Iowa 50309
United States
Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States
Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States
Missouri Baptist Medical Center
St Louis, Missouri 63131
United States
Duke University Medical Center
Durham, North Carolina 27710
United States
Case Western Reserve University
Cleveland, Ohio 44106
United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania 19111
United States
Temple University Hospital
Philadelphia, Pennsylvania 19140
United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
United States
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
United States
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah 84112
United States
Data Sources & Contacts
Full trial details
For more Information